EMEA-003246-PIP01-22

Table of contents

Key facts

Active substance
Golidocitinib
Therapeutic area
Oncology
Decision number
P/0386/2022
PIP number
EMEA-003246-PIP01-22
Pharmaceutical form(s)
Capsule, hard
Condition(s) / indication(s)
Treatment of peripheral T cell lymphoma
Route(s) of administration
Oral use
Contact for public enquiries
Dizal (Jiangsu) Pharmaceuticals Co., Ltd.

E-mail: info@dizalpharma.com
Tel: +86 2161097840

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

How useful was this page?

Add your rating